Global Bladder Cancer Therapeutics Market 2017-2021

膀胱癌治療の世界市場

◆タイトル:Global Bladder Cancer Therapeutics Market 2017-2021
◆商品コード:IRTNTR13172
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2017年5月31日
◆ページ数:70
◆資料形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療・製薬
◆販売価格オプション(消費税別)
Single User(1名利用)USD3,500 ⇒換算¥385,000見積依頼/購入/質問フォーム
Five User(~5名利用)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Enterprise License(全社内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

当調査レポートでは、膀胱癌治療の世界市場について調査・分析し、エグゼクティブサマリー、市場概観、市場概観、業界の構造分析、膀胱癌治療の世界市場規模及び予測、地域別分析/市場規模、市場の成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析などの情報をお届けいたします。

About Bladder Cancer Therapeutics
The bladder is an organ located in the lower abdominal region near the pelvic bones and acts as a reservoir of urine. A bladder cancer is characterized by the abnormal cell growth in the bladder, which impairs the proper functioning of urinary system. Majority of bladder cancer develops in the innermost layer called urothelium or transitional epithelium, composed of epithelium or transitional cells.

Technavio’s analysts forecast the global bladder cancer therapeutics market to grow at a CAGR of 4.77% during the period 2017-2021.

[Covered in this report]
The report covers the present scenario and the growth prospects of the global bladder cancer therapeutics market for 2017-2021. To calculate the market size, the report considers the sales from both branded and generic drugs.

The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA

Technavio’s report, Global Bladder Cancer Therapeutics Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

[Key vendors]
• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffman-La Roche
• Pfizer

[Other prominent vendors]
• Accord Healthcare
• AstraZeneca
• Bedford Lab
• Merck
• Sanofi

[Market driver]
• Growing prevalence rate leads to higher prescription value
• For a full, detailed list, view our report

[Market challenge]
• Economic burden of bladder cancer
• For a full, detailed list, view our report

[Market trend]
• Advent of novel pipeline
• For a full, detailed list, view our report

[Key questions answered in this report]
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

*** You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.

【資料の目次】

Table of Contents
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction
• Market outline
• Bladder
• Bladder cancer
• Currently approved therapeutic regimen
• Stages of bladder cancer

PART 05: Key clinical trials

PART 06: Market landscape
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation by therapy
• Intravesical therapy
• Chemotherapy
• Preservation therapy
• Others

PART 08: Geographical segmentation
• Bladder cancer therapeutics market in Americas
• Bladder cancer therapeutics market in EMEA
• Bladder cancer therapeutics market in APAC

PART 09: Decision framework

PART 10: Drivers and challenges
• Market drivers
• Market challenges

PART 11: Market trends
• Growing influence of targeted biologics
• Advent of novel pipeline
• Emergence of effective diagnostic tools

PART 12: Vendor landscape
• Competitive landscape

PART 13: Key vendor analysis
• Bristol-Myers Squibb
• Eli Lilly
• F. Hoffman-La Roche
• Pfizer
• Other prominent vendors

PART 14: Appendix
• List of abbreviations

[List of Exhibits]
Exhibit 01: Approved therapeutics for the treatment of bladder cancer
Exhibit 02: Stages of bladder cancer
Exhibit 03: Pipeline landscape based on development phase 2016
Exhibit 04: Key clinical trials
Exhibit 05: Snapshot of therapy-based pipeline in global bladder cancer market
Exhibit 06: Market scenario for global bladder cancer therapeutics market 2016-2021 ($ million)
Exhibit 07: Global bladder cancer therapeutics market revenue 2016-2021 ($ millions)
Exhibit 08: Opportunity analysis of global bladder cancer therapeutics market
Exhibit 09: Five forces analysis
Exhibit 10: Segmentation of global bladder cancer therapeutics market by therapy 2016
Exhibit 11: Global bladder cancer therapeutics market segmentation based on therapy 2016 (%)
Exhibit 12: Global bladder cancer therapeutics market for intravesical therapy 2016-2021 ($ millions)
Exhibit 13: Global bladder cancer therapeutics market for chemotherapy 2016-2021 ($ millions)
Exhibit 14: Global bladder cancer therapeutics market for preservation therapy 2016-2021 ($ millions)
Exhibit 15: Segmentation of global bladder cancer therapeutics market based on geography 2016 and 2021
Exhibit 16: Global bladder cancer therapeutics market revenue by geography 2016-2021 ($ millions)
Exhibit 17: Global bladder cancer therapeutics market share by geography 2016-2021 (%)
Exhibit 18: Market scenario in Americas
Exhibit 19: Bladder cancer therapeutics market in Americas 2016-2021 ($ millions)
Exhibit 20: Market scenario in EMEA
Exhibit 21: Bladder cancer therapeutics market in EMEA 2016-2021 ($ millions)
Exhibit 22: Market scenario in APAC
Exhibit 23: Bladder cancer therapeutics market in APAC 2016-2021 ($ millions)
Exhibit 24: Competitive structure analysis of global bladder cancer therapeutics market 2016
Exhibit 25: Bristol-Myers Squibb: Key highlights
Exhibit 26: Bristol-Myers Squibb: Strength assessment
Exhibit 27: Bristol-Myers Squibb: Strategy assessment
Exhibit 28: Bristol-Myers Squibb: Opportunity assessment
Exhibit 29: Eli Lilly: Key highlights
Exhibit 30: Eli Lilly: Strength assessment
Exhibit 31: Eli Lilly: Strategy assessment
Exhibit 32: Eli Lilly: Opportunity assessment
Exhibit 33: F. Hoffman-La Roche: Key highlights
Exhibit 34: F. Hoffman-La Roche: Strength assessment
Exhibit 35: F. Hoffman-La Roche: Strategy assessment
Exhibit 36: F. Hoffman-La Roche: Opportunity assessment
Exhibit 37: Pfizer: Key highlights
Exhibit 38: Pfizer: Strength assessment
Exhibit 39: Pfizer: Strategy assessment
Exhibit 40: Pfizer: Opportunity assessment



【掲載企業】

Bristol-Myers Squibb, Eli Lilly, F. Hoffman-La Roche, Pfizer, Accord Healthcare, AstraZeneca, Bedford Lab, Merck, and Sanofi.

【資料のキーワード】

膀胱癌、膀胱癌治療

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[膀胱癌治療の世界市場] (Global Bladder Cancer Therapeutics Market 2017-2021 / IRTNTR13172)販売に関する免責事項
[膀胱癌治療の世界市場] (Global Bladder Cancer Therapeutics Market 2017-2021 / IRTNTR13172)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆